Neuraxis Inc Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Neuraxis Inc has an operating margin of -266.5%, meaning the company retains $-266 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -270.9% the prior year.
Neuraxis Inc's revenue grew 9.2% year-over-year to $2.7M, a solid pace of expansion. This earns a growth score of 55/100.
Neuraxis Inc has a moderate D/E ratio of 1.30. This balance of debt and equity financing earns a leverage score of 63/100.
Neuraxis Inc's current ratio of 1.75 indicates adequate short-term liquidity, earning a score of 50/100. The company can meet its near-term obligations, though with limited headroom.
While Neuraxis Inc generated -$6.1M in operating cash flow, capex of $28K consumed most of it, leaving -$6.1M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Neuraxis Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Neuraxis Inc generates $0.74 in operating cash flow (-$6.1M OCF vs -$8.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Neuraxis Inc earns $-3199.3 in operating income for every $1 of interest expense (-$7.2M vs $2K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Neuraxis Inc (NRXS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Neuraxis Inc generated $2.7M in revenue in fiscal year 2024. This represents an increase of 9.2% from the prior year.
Neuraxis Inc's EBITDA was -$7.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 7.5% from the prior year.
Neuraxis Inc generated -$6.1M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 8.9% from the prior year.
Neuraxis Inc reported -$8.2M in net income in fiscal year 2024. This represents an increase of 43.7% from the prior year.
Neuraxis Inc earned $-1.22 per diluted share (EPS) in fiscal year 2024. This represents an increase of 72.9% from the prior year.
Neuraxis Inc held $3.7M in cash against $0 in long-term debt as of fiscal year 2024.
Neuraxis Inc had 7M shares outstanding in fiscal year 2024. This represents an increase of 7.4% from the prior year.
Neuraxis Inc's gross margin was 86.5% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 1.2 percentage points from the prior year.
Neuraxis Inc's operating margin was -266.5% in fiscal year 2024, reflecting core business profitability. This is up 4.4 percentage points from the prior year.
Neuraxis Inc's net profit margin was -306.8% in fiscal year 2024, showing the share of revenue converted to profit. This is up 287.7 percentage points from the prior year.
Neuraxis Inc invested $206K in research and development in fiscal year 2024. This represents an increase of 21.7% from the prior year.
Neuraxis Inc invested $28K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 9.8% from the prior year.
NRXS Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $811K-9.2% | $894K-0.2% | $896K+17.7% | $761K+24.5% | $612K-5.4% | $647K+21.7% | $531K+11.3% | $477K |
| Cost of Revenue | $135K-7.6% | $147K+5.1% | $139K+19.8% | $116K+58.5% | $73K-2.2% | $75K+3.8% | $72K+7.5% | $67K |
| Gross Profit | $676K-9.6% | $747K-1.2% | $756K+17.3% | $645K+19.8% | $538K-5.9% | $572K+24.5% | $459K+11.9% | $410K |
| R&D Expenses | $131K+124.4% | $58K-3.7% | $61K+203.1% | $20K-63.2% | $54K+875.1% | $6K+350.8% | -$2K-104.9% | $45K |
| SG&A Expenses | $1.9M-16.9% | $2.3M-20.7% | $2.9M+27.1% | $2.2M-14.5% | $2.6M+13.4% | $2.3M+14.9% | $2.0M-39.3% | $3.3M |
| Operating Income | -$2.1M-22.3% | -$1.7M+25.2% | -$2.3M-56.5% | -$1.5M+33.5% | -$2.2M-20.5% | -$1.8M-12.5% | -$1.6M+46.1% | -$3.0M |
| Interest Expense | $30K+120.8% | $13K+500.5% | $2K+101.3% | -$170K-310.3% | $81K+203.8% | $27K+52.6% | $17K-83.0% | $103K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$2.1M-25.6% | -$1.7M+25.8% | -$2.3M-57.4% | -$1.4M+50.4% | -$2.9M-37.6% | -$2.1M-33.2% | -$1.6M+81.5% | -$8.6M |
| EPS (Diluted) | $-0.24-9.1% | $-0.22+33.3% | $-0.33-43.5% | $-0.23+45.2% | $-0.42-31.2% | $-0.32-218.5% | $0.27+111.3% | $-2.38 |
NRXS Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.8M-18.5% | $7.1M+133.9% | $3.0M-36.3% | $4.8M+80.7% | $2.6M+178.4% | $946K+85.6% | $509K-58.8% | $1.2M |
| Current Assets | $5.0M-24.6% | $6.6M+160.5% | $2.5M-40.4% | $4.3M+102.0% | $2.1M+417.8% | $408K+68.1% | $243K-74.9% | $967K |
| Cash & Equivalents | $4.4M-26.9% | $6.0M+198.6% | $2.0M-45.8% | $3.7M+109.4% | $1.8M+2059.3% | $82K+4.1% | $79K-89.7% | $761K |
| Inventory | $110K-16.1% | $131K+251.2% | $37K-15.6% | $44K+3.8% | $43K+111.5% | $20K-4.8% | $21K-38.5% | $35K |
| Accounts Receivable | $109K-15.6% | $129K-47.3% | $244K-0.4% | $245K+66.3% | $147K+62.5% | $91K+23.7% | $73K-44.7% | $132K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.5M+23.2% | $2.8M+2.3% | $2.8M+3.0% | $2.7M-65.9% | $7.9M+91.1% | $4.1M+115.9% | $1.9M-16.7% | $2.3M |
| Current Liabilities | $3.1M+34.1% | $2.3M+11.7% | $2.1M-13.6% | $2.4M-68.0% | $7.6M+99.0% | $3.8M+102.4% | $1.9M-16.5% | $2.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $2.3M-46.3% | $4.3M+1545.5% | $258K-87.5% | $2.1M+139.3% | -$5.3M-65.1% | -$3.2M-126.9% | -$1.4M-32.2% | -$1.1M |
| Retained Earnings | -$62.9M-3.5% | -$60.8M-2.9% | -$59.1M-4.0% | -$56.8M-6.0% | -$53.6M-5.8% | -$50.7M-4.4% | -$48.6M-3.4% | -$47.0M |
NRXS Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.4M+2.7% | -$1.5M+8.5% | -$1.6M+8.8% | -$1.8M-8.9% | -$1.6M-21.2% | -$1.3M+49.3% | -$2.6M+6.6% | -$2.8M |
| Capital Expenditures | $0-100.0% | $7K-59.5% | $18K | $0-100.0% | $9K-41.0% | $15K-8.2% | $16K+499.9% | $3K |
| Free Cash Flow | -$1.4M+3.2% | -$1.5M+9.1% | -$1.6M+7.8% | -$1.8M-8.3% | -$1.6M-20.6% | -$1.3M+49.1% | -$2.6M+6.1% | -$2.8M |
| Investing Cash Flow | $0+100.0% | -$7K+59.5% | -$18K | $0+100.0% | -$9K+41.0% | -$15K+8.2% | -$16K+62.4% | -$43K |
| Financing Cash Flow | -$184K-103.4% | $5.5M+7914.3% | -$70K-101.3% | $5.2M+57.0% | $3.3M+145.0% | $1.4M-31.2% | $2.0M-45.0% | $3.6M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
NRXS Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.3%-0.3pp | 83.6%-0.8pp | 84.4%-0.3pp | 84.7%-3.3pp | 88.0%-0.4pp | 88.4%+2.0pp | 86.4%+0.5pp | 85.9% |
| Operating Margin | -258.8%-66.7pp | -192.1%+64.1pp | -256.3%-63.6pp | -192.7%+168.2pp | -360.9%-77.6pp | -283.3%+23.1pp | -306.4%+326.6pp | -633.0% |
| Net Margin | -261.6%-72.5pp | -189.1%+65.3pp | -254.4%-64.2pp | -190.2%+286.9pp | -477.1%-149.2pp | -327.9%-28.3pp | -299.6%+1506.9pp | -1806.5% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -36.8%-12.9pp | -23.8%+51.4pp | -75.2%-44.8pp | -30.4%+80.4pp | -110.8%+113.4pp | -224.2%+88.3pp | -312.5%+385.4pp | -697.9% |
| Current Ratio | 1.58-1.2 | 2.82+1.6 | 1.21-0.5 | 1.75+1.5 | 0.28+0.2 | 0.11-0.0 | 0.13-0.3 | 0.43 |
| Debt-to-Equity | 1.53+0.9 | 0.67-10.1 | 10.72+9.4 | 1.30+2.8 | -1.50-0.2 | -1.30+0.1 | -1.36+0.8 | -2.16 |
| FCF Margin | -175.9%-11.0pp | -164.9%+16.1pp | -181.1%+49.9pp | -231.0%+34.6pp | -265.6%-57.3pp | -208.3%+289.5pp | -497.8%+92.6pp | -590.4% |
Similar Companies
Frequently Asked Questions
What is Neuraxis Inc's annual revenue?
Neuraxis Inc (NRXS) reported $2.7M in total revenue for fiscal year 2024. This represents a 9.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Neuraxis Inc's revenue growing?
Neuraxis Inc (NRXS) revenue grew by 9.2% year-over-year, from $2.5M to $2.7M in fiscal year 2024.
Is Neuraxis Inc profitable?
No, Neuraxis Inc (NRXS) reported a net income of -$8.2M in fiscal year 2024, with a net profit margin of -306.8%.
What is Neuraxis Inc's earnings per share (EPS)?
Neuraxis Inc (NRXS) reported diluted earnings per share of $-1.22 for fiscal year 2024. This represents a 72.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Neuraxis Inc's EBITDA?
Neuraxis Inc (NRXS) had EBITDA of -$7.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Neuraxis Inc's gross margin?
Neuraxis Inc (NRXS) had a gross margin of 86.5% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Neuraxis Inc's operating margin?
Neuraxis Inc (NRXS) had an operating margin of -266.5% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Neuraxis Inc's net profit margin?
Neuraxis Inc (NRXS) had a net profit margin of -306.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Neuraxis Inc's free cash flow?
Neuraxis Inc (NRXS) generated -$6.1M in free cash flow during fiscal year 2024. This represents a 8.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Neuraxis Inc's operating cash flow?
Neuraxis Inc (NRXS) generated -$6.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Neuraxis Inc's total assets?
Neuraxis Inc (NRXS) had $4.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Neuraxis Inc's capital expenditures?
Neuraxis Inc (NRXS) invested $28K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Neuraxis Inc spend on research and development?
Neuraxis Inc (NRXS) invested $206K in research and development during fiscal year 2024.
How many shares does Neuraxis Inc have outstanding?
Neuraxis Inc (NRXS) had 7M shares outstanding as of fiscal year 2024.
What is Neuraxis Inc's current ratio?
Neuraxis Inc (NRXS) had a current ratio of 1.75 as of fiscal year 2024, which is generally considered healthy.
What is Neuraxis Inc's debt-to-equity ratio?
Neuraxis Inc (NRXS) had a debt-to-equity ratio of 1.30 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Neuraxis Inc's return on assets (ROA)?
Neuraxis Inc (NRXS) had a return on assets of -173.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Neuraxis Inc's cash runway?
Based on fiscal year 2024 data, Neuraxis Inc (NRXS) had $3.7M in cash against an annual operating cash burn of $6.1M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Neuraxis Inc's Piotroski F-Score?
Neuraxis Inc (NRXS) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Neuraxis Inc's earnings high quality?
Neuraxis Inc (NRXS) has an earnings quality ratio of 0.74x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Neuraxis Inc cover its interest payments?
Neuraxis Inc (NRXS) has an interest coverage ratio of -3199.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Neuraxis Inc?
Neuraxis Inc (NRXS) scores 34 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.